Fidelity Top Stories
Second wave of Covid-19 in Europe could have peaked in UK - report
The second wave in Europe could have already peaked in some countries such as the UK, according to the latest report from Imperial College London.
EU denies FT Tweets on state aid Brexit breakthrough - report
EU officials said no “landing zones” were in sight trade talks with the UK, an official with the bloc reportedly said on Thursday after Tweets by a Financial Times reporter citing British officials saying this was the case boosted the pound.
Halfords shares soar on profit guidance upgrade after bike sales surge
Halfords shares soared on Thursday after the company raised profit guidance on the back of surging demand for bikes during the coronavirus pandemic and added that it intended to hire hundreds of new technicians.
Rolls-Royce in £3bn cash call, bond offering to bolster finances
Aircraft engine maker Rolls-Royce unveiled plans to raise up to £5bn through a debt and equity raising to shore up its balance sheet in the face of the coronavirus pandemic.
EU starts legal case against UK over Internal Market Bill
The European Union on Thursday launched legal action against the UK’s new Internal Market Bill on the grounds that it breached the Brexit Withdrawal Agreement and breaks international law.
Mailbox set to list on London's new IPSX
Mailbox has set out its plans to become the first single-asset real estate investment trust listed on the new International Property Securities Exchange.
UK factory output very near early 2020 level, PMI shows
Manufacturing sector activity in the UK slowed by a bit more than anticipated last month, but output was now very close to the levels seen at the start of 2020, although that might not last for too long.
Moderna Covid-19 vaccine may be ready for full-scale use by early Q2 2020
Moderna's Covid-19 vaccine candidate will not be ready by the 3 November presidential elections in the US, but it could be by the end of that month.
FDA expands probe into AstraZeneca Covid-19 vaccine candidate
American health regulators have widened their investigation into the adverse event related to one patient in AstraZeneca's ongoing phase three clinical trial of its Covid-19 vaccine candidate.